
This is what Queen Latifah wants you to know about obesity and health risks
This is what Queen Latifah wants you to know about obesity and health risks
Show Caption
Hide Caption
Victoria's Secret runway show brought out the stars
Stars stole the show at the Victoria's Secret runway show in New York.
Queen Latifah wants the world to know obesity is a disease, one often tainted with stigma.
The Grammy Award-winning musician and actress opened up about the public awareness campaign, Truth About Weight, which highlights the risks of obesity, including cardiovascular diseases such as heart attack or stroke.
"Obesity is a disease and should be treated as such − not treated as some sort of character flaw or people not trying hard enough," the rap pioneer told USA TODAY.
Latifah, 55, said her involvement in the Novo Nordisk-funded campaign is about "changing the stigma, changing the bias and opening a door to people who are dealing with obesity."
People with obesity at risk of heart disease, the nation's top killer
Two in 5 adults in the United States have obesity, according to the Centers for Disease Control and Prevention. The rate is even greater for Black women, research shows.
People who have obesity are at greater risk of heart disease, which is the nation's top killer, resulting in more than 700,000 deaths per year, the CDC said. Heart disease tops cancer, motor vehicle crashes and respiratory diseases as a cause of death.
"The Equalizer" star said it's important for people to acknowledge and fight stigma associated with obesity. She said people with obesity and their loved ones also should be aware that medicine and science can help.
Latifah's mother, Rita Owens, died in 2018 after a long battle with a heart condition. And Latifah said said her cousin, died from obesity and its effects.
"Having lost a cousin to obesity and its effects − a cousin who was one of my funniest cousins, my coolest cousin, who had eight kids to raise − was sad to see. That was really rough," Latifah said. "Other families should not have to go through that."
Latifah urged people with obesity − and their loved ones − to educate themselves about the disease.
"The more information you have as a patient, the more you can speak with your doctor honestly and openly," the "Girls Trip" star said. "Send them to work a little bit. They go to school for this. This is what they train to do. They are a doctor."
Study: Even doctors must acknowledge weight bias
Latifah said everyone, including the medical community, can do their part to combat weight bias.
"Is your doctor's office set up to take care of all patients?" Latifah said. "Do you have a chair for someone that is bigger bodied? Are you prepared for that?"
A study published May 13 in BMJ Open Diabetes Research and Care said weight bias can contribute to stress, weight gain and psychological effects such as depression, anxiety and poor body image. The study highlighted new guidance from the Obesity Association, a division of American Diabetes Association, to recognize and address weight bias and stigma.
Doctors can fight weight bias through steps such as equipping medical offices with waiting room chairs, exam tables and medical equipment for people of all sizes, the study said.
"Every person, no matter of their size, deserves kindness, dignity and high quality (health care)," said Dr. Nuha El Sayed, who is leading the association's development of the standards.
Even some medical experts say the definition of obesity − a person who has a body mass index of 30 or more − needs to change. The Lancet commission in January recommended new measures of obesity to add nuance to adequately explain a person's risks and what they can do to maintain health.
Latifah credits upbringing for strength to combat weight bias
Latifah opened up about her own body image issues, which she first noticed as a child growing up in Newark and East Orange, New Jersey.
"When your mother looks like Diahann Carroll and your father looks like Billy Dee Williams, you're wondering, 'What's wrong with me?'" Latifah said. "I hadn't grown into being Queen Latifah − nowhere near it."
As a young girl, she was said she was cut from her kickball team. But her mother consoled her, nurtured her and built her up − infusing the young girl with confidence to excel in other sports, singing and acting.
She said that confidence helped her break into what was then a male-dominated rap genre in the late 1980s and early 1990s. She also landed her role on the Fox sitcom "Living Single," which ran from 1993 to 1998.
"There weren't a whole lot of sitcoms with people who look like me starring in them," Latifah said. "But I knew I could do it, and it was a lot of convincing everyone else, the powers that be, that I could do it."
As her acting career blossomed in the 1990s and 2000s, she also gained recognition in 2006 as the first hip hop artist to earn a star on the Hollywood Walk of Fame.
She hopes that inspires other young girls to achieve their dreams.
"There's nothing more beautiful to me than a confident woman who walks in a room and owns that room based on her confidence, not what her body looks like," Latifah said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Mayor Walsh to proclaim Tourette Syndrome Awareness Day
SYRACUSE. N.Y. (WSYR-TV)– Syracuse Mayor Walsh Ben has declared June 7 Tourrette Syndrome Awareness Day in Syracuse, NY. Tourette Syndrome is a neurological condition that involves involuntary, repetitive movements and vocalizations known as tics. Mayor Walsh, Councilmember Nave, families impacted by Tourette Syndrome and other Tic Disorders, and members of the Syracuse community will gather on the steps of City Hall on June 6, at noon to announce the proclamation. Recognizing the disorder will help raise awareness, educate, and promote inclusion for individuals living with Tourette Syndrome and other Tic Disorders. It will also increase supportive environments where people, regardless of their neurological disorder, can grow. According to the Centers for Disease Control and Prevention (CDC), approximately one in 50 school-aged children in the US are affected by Tourette Syndrome or a Tic Disorder, including many families in Syracuse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
From HIV to Hormone Therapy, Medicaid Cuts Threaten Atlanta's LGBTQ+ Community
As lawmakers push for sweeping cuts to Medicaid, fear weighs heavily on Tori Cooper. Cooper, a trans woman who serves as the director of strategic outreach and training for the Human Rights Campaign, told Capital B Atlanta that for her and other Black trans residents, these cuts will have a detrimental impact on their lives. 'The Black LGBTQ community will be greatly impacted, and Black trans folks even more so,' said Cooper. 'For years, we've acknowledged how systematic racism impacts the lives of Black LGBTQ people. Inequity and racist ideology and policies have traditionally led to worse health outcomes for poor, less educated, underemployed people and those of us who live in the South.' Last month, congressional House Republicans passed a bill that would cut billions over the next 10 years from Medicaid, the federal-state health care insurance program that helps pay for health care for low-income people. The bill also would prohibit gender transition care from being covered by the program. 'I worry that preventable health conditions like HIV will ravage my community,' Cooper said. 'I worry that Black trans people will lose some of the social and political traction that our transestors fought for. I worry that my Black trans family will have to go back into the proverbial closet for safety. Closets are made for clothes, not people.' Cooper worries that in a place like Georgia, where HIV rates are high and access to health care is already difficult due to the Georgia General Assembly's refusal to expand Medicaid, the Black LGBTQ+ community will be one of the vulnerable and bear the brunt of these looming cuts. In 2023, about 1 in every 4 Black Georgians was covered by Medicaid, compared to about 1 in every 10 white Georgians, according to the State Health Access Data Assistance Center. Nationally, Black LGBTQ residents are twice as likely to be enrolled in Medicaid compared to the general population, Victoria Kirby York, director of public policy and programs for the National Black Justice Coalition, told Capital B Atlanta. York said she's fearful that critical areas of health care for Black LGBTQ+ residents such as gender-affirming care, mental health services, and substance abuse treatment will all be impacted by the Medicaid cuts. 'Thirty-two percent of [LGBTQ people] versus 15% of the general population use Medicaid in order to access health care, and that number is even higher for transgender members of our community, where 45% of the community are relying on Medicaid,' York said. Although Georgia is one of the 10 states that did not expand Medicaid, leaving hundreds of thousands of residents uninsured, the proposed budget cuts will still be felt. The state could potentially lose billions in federal Medicaid funding, and hundreds of thousands of Georgians could lose Medicaid coverage over the next 10 years, according to reporting from the Kaiser Family Foundation. Matthew Rose, senior public policy advocate with the Human Rights Campaign, told Capital B Atlanta these cuts will put a strain on the state's budget, resulting in a push by state lawmakers to make 'draconian' decisions on how to further cut costs. This could mean cutting back on some of the optional health services and medicines provided underneath Medicaid in Georgia, such as HIV preventative medications or mental health services, or lawmakers could tighten eligibility requirements so fewer residents are covered by the insurance program. When it comes to HIV, Maxx Boykin, the campaign manager for Save HIV Funding, told Capital B Atlanta he worries Medicaid cuts could exacerbate the already high HIV transmission rates in the state, as many people living with HIV rely on Medicaid for medication and wraparound services like home health care and therapy. Read More: CDC Cuts HIV Communications, Leaving Vulnerable Black Georgians in the Dark According to the Kaiser Family Foundation, Medicaid is the largest source of insurance coverage for people with HIV in the United States, covering an estimated 40% of the nonelderly adults with HIV, compared to just 15% of the nonelderly adult population overall. According to the CDC, Georgia had the second-highest HIV diagnosis rate and the second-highest rate of HIV related deaths in 2023 in the U.S. Additionally, Georgia had the highest rate of new HIV infections in 2022. In addition, despite constituting about 32% of Georgia's population, Black people accounted for approximately 71% of new HIV diagnoses in 2021. 'When thinking about HIV, that means less people will have access to the medications that they need, and we will see an even larger spread of HIV in our communities, and a big part of that will be because the majority of people living with HIV actually need Medicaid,' said Boykin. Maisha Standifer, the director of population health at the Satcher Health Leadership Institute at the Morehouse School of Medicine, said the elderly and those with disabilities shouldn't be forgotten when thinking about Medicaid and the LGBTQ community. According to the Human Rights Campaign, in the U.S., LGBTQ+ adults, and transgender adults in particular, were significantly more likely than non-LGBTQ+ adults to self-report having at least one disability. Standifer said that for Georgia's Medicaid program, people ages 65 and older and people with disabilities account for more than half of the state's $16 billion Medicaid spending. 'We have community partners who are 30-plus years living with HIV and aging. So with aging naturally comes other chronic conditions. We're talking about diabetes, cancer, heart disease,' said Standifer. The cuts to Medicaid are part of the Trump administration's efforts to curb federal spending to offset the cost of extending the president's 2017 tax cuts for high-income earners. Of further concern to Rose with the Human Rights Campaign is the impact on the LGBTQ community when the Medicaid cuts are layered on top of the proposed SNAP cuts in the bill, creating even more harm to LGBTQ people's health. 'We've seen the result of what hunger can do, which is why we feed people, why we created these programs in the first place, and the SNAP cuts would be devastating. … Then you tack them on to the fact that you're not eating as much, which weakens your immune system, and so it makes it easier for you to get sick, so it's a compounding issue,' said Rose. While the Medicaid cuts are still under review in the Senate, advocates are encouraging anyone in opposition to the cuts to reach out to their representatives and share their concerns about the proposed legislation. 'We need to hold our elected officials accountable, both on the federal side, the state side, and our local side, to make sure they're actually doing what's right for folks,' said Boykin. The post From HIV to Hormone Therapy, Medicaid Cuts Threaten Atlanta's LGBTQ+ Community appeared first on Capital B News - Atlanta.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Key presentations include two updates from a phase 3 trial evaluating investigational treatment with Mim8 (denecimig) and five assessing treatment outcomes with concizumab in hemophilia A phase 3 trial analysis from FRONTIER5 will evaluate the safety of switching directly from emicizumab to Mim8 (denecimig) in people living with hemophilia A/B Findings from explorer7 and explorer8 phase 3 trials will assess data including non-joint bleeds, annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B PLAINSBORO, N.J., June 6, 2025 /PRNewswire/ -- Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction, and global real-world diagnosis and treatment data for joint bleeds. "At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition." New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors.1 Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8. In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds, and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors. Summary of presentationsAccepted data at the 33rd ISTH Congress includes the following poster and oral presentations. Additional information can be found on the ISTH website. Full details of Novo Nordisk abstracts to be presented: Abstract title Abstract presentationdetails Hemophilia Investigational Mim8 FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Oral presentation June 22 2:45-4:00 pm EST OC 20.4 Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 Poster presentation June 23 1:45-2:45 pm EST PB0812 Mim8 enhances procoagulant activity of select hemophilia B-causing Factor IX variants (research collaboration) Oral presentation June 21 1:00-1:15 pm EST OC 03.1 Concizumab Non-joint bleeds in patients with hemophilia A or B with inhibitors: Concizumab explorer7 study Poster presentation June 23 1:45-2:45 pm EST PB0851 Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Oral presentation June 24 2:45-4:00 pm EST OC 59.2 The effect of concizumab on thrombin generation in FVII deficient plasma Poster presentation June 24 1:45-2:45 pm EST PB1478 ISS study: TFPI slows prothombinase assembly when concizumab is bound to its second Kunitz domain Poster presentation June 24 1:45-2:45 pm EST PB1358 Taiwan study: Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors Poster presentation June 23 1:45-2:45 pm EST PB0869 Pre-clinical data & general hemophilia In vitro activity of Inno8 in global hemostatic assays alone and with other hemostatic agents Oral presentation June 23 2:45-4:00 pm EST OC 39.5 Genomic integration of FVIII transgene in hepatocytes restores durable FVIII activity in vivo Oral presentation June 24 9:30-10:45 am EST OC 51.2 US physician-reported prophylactic treatment satisfaction and joint health of people with hemophilia Poster presentation June 24 1:45-2:45 pm EST PB1485 Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data Poster presentation June 24 1:45-2:45 pm EST PB1423 About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.2 It is estimated to affect approximately 1,125,000 people worldwide.3 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).2 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy. However, sometimes the body can produce inhibitors as an immune response to the clotting factor replacement therapy. When this happens, the therapy may not work and can limit treatment options.5 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. MedlinePlus. Hemophilia. Accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al.; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of hemophilia. Accessed May 2025. Available at Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NNG00026 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Sign in to access your portfolio